Agenus (AGEN) Misses Q1 EPS by 23c

Agenus (NASDAQ: AGEN) reported Q1 EPS of ($0.53), $0.23 worse than the analyst estimate of ($0.30).

"Innovation and speed are the basis of our I-O business model with 5 INDs filed over the past 18 months, 6 INDs on track for this year and 2 additional INDs planned in the 1H of next year. We have treated over 100 patients with our CTLA-4 (AGEN1884) and/or PD-1 (AGEN2034) antibodies with clinical responses in some of the patients with advanced cancers," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus. " We have also made progress with our commercial readiness with commercial grade antibodies already produced; our partnering discussions are maturing, and we are committed to bring these discussions to closure."

For earnings history and earnings-related data on Agenus (AGEN) click here.

You May Also Be Interested In

• American Express (AXP) down despite beating Q1 estimates on top and bottom lines
• MetroCity Bankshares, Inc. (MCBS) Tops Q1 EPS by 4c
• Agenus Inc. (AGEN) PT Lowered to $35 at Baird